Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicofuranose is a nicotinic acid derivative that serves as a prodrug of niacin (nicotinic acid). Chemically, it is the tetranicotinic acid ester of fructose, specifically 1,3,4,6-tetranicotinoyl-fructofuranose. It was historically used as an antihyperlipidemic agent and a peripheral vasodilator. By slowly releasing nicotinic acid into the bloodstream upon hydrolysis, nicofuranose helps to mitigate the intense cutaneous flushing often associated with immediate-release nicotinic acid formulations. Its therapeutic applications included the treatment of hyperlipidemia and various peripheral vascular disorders, such as Raynaud's disease and arteriosclerosis obliterans, by improving blood circulation and lowering serum cholesterol and triglyceride levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicofuranose.